Trexquant Investment LP Acquires Shares of 65,858 Janux Therapeutics, Inc. (NASDAQ:JANX)

Trexquant Investment LP bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 65,858 shares of the company's stock, valued at approximately $3,526,000. Trexquant Investment LP owned about 0.13% of Janux Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in JANX. Wellington Management Group LLP boosted its holdings in shares of Janux Therapeutics by 3,592.9% in the fourth quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock worth $28,665,000 after buying an additional 520,898 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Janux Therapeutics by 2,519.6% during the 4th quarter. Franklin Resources Inc. now owns 497,287 shares of the company's stock worth $26,625,000 after acquiring an additional 478,304 shares during the last quarter. Pictet Asset Management Holding SA purchased a new position in shares of Janux Therapeutics during the 4th quarter worth $20,602,000. Vanguard Group Inc. grew its position in shares of Janux Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after acquiring an additional 288,402 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Janux Therapeutics by 715.0% in the 4th quarter. Victory Capital Management Inc. now owns 242,409 shares of the company's stock worth $12,979,000 after purchasing an additional 212,664 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several analysts have issued reports on JANX shares. Wedbush reissued an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank dropped their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Finally, William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $92.44.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. The trade was a 1.10 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,640,768.85. This trade represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 29.40% of the company's stock.

Janux Therapeutics Stock Up 7.2 %

JANX stock traded up $1.93 during mid-day trading on Friday, hitting $28.80. The company had a trading volume of 2,018,926 shares, compared to its average volume of 858,288. The company has a 50-day moving average price of $31.72 and a 200 day moving average price of $44.16. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -24.62 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.